Detalles de la búsqueda
1.
New Opportunities for the Utilization of the Sulfoximine Group in Medicinal Chemistry from the Drug Designer's Perspective.
Chemistry
; 28(56): e202201993, 2022 Oct 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35789054
2.
The Kinase Chemogenomic Set (KCGS): An Open Science Resource for Kinase Vulnerability Identification.
Int J Mol Sci
; 22(2)2021 Jan 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33429995
3.
Increasing Complexity: A Practical Synthetic Approach to Three-Dimensional, Cyclic Sulfoximines and First Insights into Their in Vitro Properties.
Chemistry
; 26(19): 4378-4388, 2020 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31961028
4.
Synthesis of Highly Enantioenriched Sulfonimidoyl Fluorides and Sulfonimidamides by Stereospecific Sulfur-Fluorine Exchange (SuFEx) Reaction.
Chemistry
; 26(55): 12533-12538, 2020 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32428384
5.
Exploration of Novel Chemical Space: Synthesis and in vitro Evaluation of N-Functionalized Tertiary Sulfonimidamides.
Chemistry
; 24(37): 9295-9304, 2018 Jul 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29726583
6.
A New, Practical One-Pot Synthesis of Unprotected Sulfonimidamides by Transfer of Electrophilic NH to Sulfinamides.
Chemistry
; 23(60): 15189-15193, 2017 Oct 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-28833686
7.
Sulfoximines: a neglected opportunity in medicinal chemistry.
Angew Chem Int Ed Engl
; 52(36): 9399-408, 2013 Sep 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-23934828
8.
European Medicinal Chemistry Leaders in Industry (EMCL) - On the Status and Future of Medicinal Chemistry Research in Europe.
ChemMedChem
; 18(13): e202300127, 2023 07 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37276375
9.
Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer.
J Med Chem
; 64(15): 11651-11674, 2021 08 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34264057
10.
BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies.
J Med Chem
; 64(17): 12723-12737, 2021 09 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34428039
11.
Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models.
J Med Chem
; 63(13): 7293-7325, 2020 07 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32502336
12.
The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models.
Mol Cancer Ther
; 19(1): 26-38, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31582533
13.
Off-target decoding of a multitarget kinase inhibitor by chemical proteomics.
Chembiochem
; 10(7): 1163-74, 2009 May 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-19350611
14.
Discovery of BAY-298 and BAY-899: Tetrahydro-1,6-naphthyridine-Based, Potent, and Selective Antagonists of the Luteinizing Hormone Receptor Which Reduce Sex Hormone Levels in Vivo.
J Med Chem
; 62(22): 10321-10341, 2019 11 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-31670515
15.
Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemia.
Oncotarget
; 9(41): 26353-26369, 2018 May 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-29899864
16.
Novel Pieces for the Emerging Picture of Sulfoximines in Drug Discovery: Synthesis and Evaluation of Sulfoximine Analogues of Marketed Drugs and Advanced Clinical Candidates.
ChemMedChem
; 12(7): 487-501, 2017 04 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28221724
17.
Identification of Atuveciclib (BAYâ 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer.
ChemMedChem
; 12(21): 1776-1793, 2017 11 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28961375
18.
Conformational Adaption May Explain the Slow Dissociation Kinetics of Roniciclib (BAY 1000394), a Type I CDK Inhibitor with Kinetic Selectivity for CDK2 and CDK9.
ACS Chem Biol
; 11(6): 1710-9, 2016 06 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-27090615
19.
BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients.
Oncotarget
; 7(5): 6015-28, 2016 Feb 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-26760770
20.
Rapid Assembly of Oligosaccharides: Total Synthesis of a Glycosylphosphatidylinositol Anchor of Trypanosoma brucei.
Angew Chem Int Ed Engl
; 37(24): 3423-3428, 1998 Dec 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-29711276